999984 | 4ME 16:0 Diether PC
1,2-di-O-phytanyl-sn-glycero-3-phosphocholine
4ME 16:0 Diether PC
1,2-di-O-phytanyl-sn-glycero-3-phosphocholine
- ChemDraw File
- 3D Structure
- Structure
- Safety Data Sheet
- Safety Data Sheet
Salvador-Castell M, Demé B, Oger P, Peters J. Lipid phase separation induced by the apolar polyisoprenoid squalane demonstrates its role in membrane domain formation in archaeal membranes. Langmuir. 2020 Jun 9. doi: 10.1021/acs.langmuir.0c00901. Epub ahead of print. PMID: 32515591.
PubMed ID: 32515591Salvador-Castell M, Demé B, Oger P, Peters J. Structural Characterization of an Archaeal Lipid Bilayer as a Function of Hydration and Temperature. Int J Mol Sci. 2020 Mar 6;21(5):1816. doi: 10.3390/ijms21051816. PMID: 32155764; PMCID: PMC7084678.
PubMed ID: 32155764Salvador-Castell M, Brooks NJ, Peters J, Oger P. Induction of non-lamellar phases in archaeal lipids at high temperature and high hydrostatic pressure by apolar polyisoprenoids. Biochim Biophys Acta Biomembr. 2020 Feb 1;1862(2):183130. doi: 10.1016/j.bbamem.2019.183130. Epub 2019 Nov 14.
PubMed ID: 31734311Rokitskaya TI, Terekhova NV, Khailova LS, Kotova EA, Plotnikov EY, Zorov DB, Tatarinov DA, Antonenko YN. Zwitterionic Protonophore Derived from 2-(2-Hydroxyaryl)alkenylphosphonium as an Uncoupler of Oxidative Phosphorylation. Bioconjug Chem. 2019 Sep 18;30(9):2435-2443. doi: 10.1021/acs.bioconjchem.9b00516. Epub 2019 Aug 16.
PubMed ID: 31374173Taylor GJ, Heberle FA, Seinfeld JS, Katsaras J, Collier CP , Sarles SA. Capacitive Detection of Low-Enthalpy, Higher-Order Phase Transitions in Synthetic and Natural Composition Lipid Membranes.Langmuir. 2017 Sep 26;33(38):10016-10026. doi: 10.1021/acs.langmuir.7b02022. Epub 2017 Sep 5.
PubMed ID: 28810118Su Z, Shodiev M, Leitch JJ, Abbasi F, Lipkowski J. The role of transmembrane potential and defects on permeabilization of lipid bilayers by alamethicin, an ion channels forming peptide. Langmuir. 2018 May 3. doi: 10.1021/acs.langmuir.8b00928.
PubMed ID: 29722994- Certificate of Analysis(Lot No. 999984C-10MG-A-017and 6394CIA017)
- Certificate of Analysis(Lot No. 999984P-10MG-A-017and 6394PIA017)
- Certificate of Analysis(Lot No. 999984P-10MG-B-017and 6394PIB017)
- Certificate of Analysis(Lot No. 999984P-10MG-C-017and 6394PIC017)
- Certificate of Analysis(Lot No. 999984P-200MG-A-017and 6394PNA017)
- Certificate of Analysis(Lot No. 999984P-10MG-D-017and 6394PID017)
- Certificate of Analysis(Lot No. 999984C-10MG-B-017and 6394CIB017)
- Certificate of Analysis(Lot No. 999984C-10MG-C-017and 6394CIC017)
- Certificate of Analysis(Lot No. 999984C-10MG-D-017and 6394CID017)
- Certificate of Analysis(Lot No. 999984C-10MG-F-017and 6394CIF017)
- Certificate of Analysis(Lot No. 999984P-10MG-F-017and 6394PIF017)
- Certificate of Analysis(Lot No. 999984P-10MG-G-017and 6394PIG017)
AvantiPolarLipids公司是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品，由于其产品的高纯度而享誉全球。40年来，AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大，其纯度之高也是无人能及。 AvantiPolarLipids,Inc.,hasalonghistoryof50yearscreatingthehighestpuritylipidsavailable.Ourpassionforhighqualityanduniqueproductsisonlyexceededbyourexcellentreputationinthemarketplace. Althoughweareknownforourlipids,weareMorethanLipids.Weoffersolutionsfortheentireproductcycle…ResearchtoCommercialization. AvantiPolarLipids公司的主要产品和服务包括：（1）ResearchProductsHighestPurityLipidReagents（2）cGMPManufacturingAPI&ContractManufacturing（3）AdjuvantsImmunotherapy&VaccineDevelopment（4）AnalyticalServicesLipidAnalysis（5）LipidomicsMassSpecStandards,Antibodies&LipidToolbox（6）Formulationsliposomes&Nanoparticles（7）EquipmentLiposomeProductionTools（8）CustomServicesSynthesis&Beyond
AvantiPolarLipids是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品，由于其产品的高纯度而享誉全球。40年来，AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大，其纯度之高也是无人能及。
AvantiPolarLipidsInc,是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至百公斤级的磷脂类和甾体类中间体和试剂。主要产品Naturalsphingolipids天然鞘脂类Naturalphospholipids天然磷脂类Naturallipidsbyextraction天然提取脂类Referencestandards相关标准品Syntheticsphingolipids合成鞘脂类--Sphingosines&S-1-P鞘氨醇和鞘氨醇-1-磷酸盐--Ceramides神经酰胺--Sphingomyelins鞘磷脂--Sphingosine&ceramidederivatives鞘氨醇及神经酰胺衍生物--Sphinganine&derivatives鞘氨醇及其衍生物--C17sphingolipids十七碳鞘脂类--C20sphingolipids二十碳鞘脂类--Phytosphingosine&derivatives植物鞘氨醇及其衍生物Syntheticlipids&phospholipids合成脂质与磷脂--PC卵磷脂--PA磷脂酸--PE脑磷脂--PG磷脂酰甘油--PS磷脂酰丝氨酸--PI,PIP2&PIP3磷脂酰肌醇，磷脂酰肌醇-4,5-二磷酸，磷脂酰-3,4,5-三磷酸--CA胆酸--LysoPC溶源性卵磷脂--LysoPA溶源性磷脂酸--LysoPAAnalogues溶源性磷脂酸类似物--Lysobio-PA溶源性双磷脂酸--LysoPE,PG&PS溶源性脑磷脂，磷脂酰甘油和磷脂酰丝氨酸--AlkylPC烷基卵磷脂--Diether&Diphytanoyletherlipids二醚与二植烷醚脂质--PAF血小板活化因子--AcylPAFAnalog酰化血小板活化因子类似物--Brominatedphosphocholines溴代胆碱磷酸--Alkylphosphatederivatives烷基磷酸盐衍生物--Plasmalogen缩醛磷脂--Functionalizedlipids功能性脂类--Biotinylatedlipids生物素酰化脂质--Bioactivelipids生物活性脂类Syntheticphospholipids合成磷酸--AcylcoenzymeA乙酰辅酶A--Metabolicintermediates代谢中间产物--Adhesivelipid粘合脂质--pHsensitivelipids酸度计用脂质Transfectionreagents转染试剂Sterolderivatives甾酮衍生物Lipidblends混合脂质Glycosylatedphospholipids糖化磷脂Fluorinatedphospholipids氟化磷脂Chelators螯合剂Pre-mixedlipidsforbicelleformation构型分析用预混合脂质Diacylglycerols&analogues甘油二酯与类似物Deuteriumlabeledlipids氘标记脂质C13PC碳-13标记卵磷脂DoxylPC自旋标记卵磷脂TempoPCTempo（4-氧-4-羟-四甲基呱啶氮氧自由基）标记卵磷脂Fluoresecentsphingolipids荧光标记鞘脂类--Omegalabeled欧米加标记物--Fattyacidlabeled脂肪酸标记物Fluoresecentcholesterol荧光标记胆固醇Fluoresecentphospholipids荧光标记磷脂--Fattyacidlabeled脂肪酸标记物--Headgrouplabeled首基标记物Polymerizablelipids聚合脂质Poly（Ethyleneglycol）-lipidconjugates共轭聚脂质FunctionalizedPEGlipids功能PEG脂质Analyticalservices分析服务Drugdeliveryproduct药物运送载体Bulklipidsforpharmaceuticalproduction工业级脂质Equipment设备
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.
磷脂C、H、O、N、P固醇C、H、ODNA 和RNA一样 CHONP
多肽和蛋白质类激素（不可口服）：促甲状腺激素释放激素，促甲状腺激素，促性腺激素、生长激素，催乳素，胰岛素，胰高血糖素，
氨基酸类衍生物（可口服）：甲状腺激素、肾上腺素
脂质类激素：（可口服）性激素和孕激素
蛋白质类激素不能口服，因会被消化液中的蛋白酶分解（——这是原因）
这是我们老师说的哦！！希望对你有帮助
为了帮助临床医师客观地了解NSAIDs，避开制药公司的导向以便更好地指导临床实践，本报请广州中山大学附属第一医院风湿免疫内科杨岫岩教授向读者介绍NSAIDs临床应用的一些问题。
NSAIDs的发展
从乙酰水杨酸（阿司匹林）应用至临床到现在，已经超过１００个年头。１９４８年第一个非水杨酸类的ＮＳＡＩＤｓ保泰松问世后，抗炎镇痛药的种类迅速增加，如吲哚美辛、双氯芬酸、布洛芬、萘普生等，使ＮＳＡＩＤｓ“家族”迅速壮大。作为其“元老”的保泰松，虽然具有很强的抗炎镇痛作用，但潜在的严重副作用（再生障碍性贫血等）使其被淘汰。
１９７１年，环氧化酶（ＣＯＸ）理论解释了ＮＳＡＩＤｓ的作用机制。ＮＳＡＩＤｓ通过抑制ＣＯＸ，阻止花生四烯酸转变为前列腺素，后者既是炎症介质，又有生理功能。因此ＮＳＡＩＤｓ在抗炎镇痛的同时可引起胃肠道反应。２０年后，研究者发现，ＣＯＸ存在不同的异构体，从而提出了ＣＯＸ异构体理论。认为ＣＯＸ存在两个异构体，一个是构建型的，称ＣＯＸ－１，以维持生理平衡为主；另一个是诱导型的称ＣＯＸ－２，主要参与炎症性前列腺素合成。
１９９４年，氟舒胺成为第一个被报道在实验室证实具有选择性ＣＯＸ－２抑制作用的ＮＳＡＩＤｓ，但在１９９６年ＩＩＩ期临床试验总结时发现，该药具有肝毒性而未能获准上市。１９９５年Ｌａｎｃｅｔ上首先称萘丁美酮、美洛昔康、尼美舒利等为“选择性ＣＯＸ－２抑制剂”，虽然同年该期刊刊出几篇读者来信，对此提法提出争议，但是后来人们仍普遍接受这种提法。１９９９年，针对ＣＯＸ异构体理论研制的昔布类药物（塞来昔布和罗非昔布）上市，被称为“特异性ＣＯＸ－２抑制剂”。
虽然ＣＯＸ异构体理论尚需完善，但它的确是新型ＮＳＡＩＤｓ研制的一个突破口。除已经问世的昔布类药物外，新的昔布类Ｅｔｏｒｉｃｏｘｉｂ、ｐａｒｅｃｏｘｉｂ、ｖａｌｄｅｃｏｘｉｂ也将投入临床。新研制的ＣＯＸ－２抑制剂不只限于昔布类，磺酰苯胺类也是研制新型ＣＯＸ－２抑制剂的方向，如氟舒胺、ＮＳ－３９８、ＨＮ－５６２４９等。另外，针对ＣＯＸ和脂氧化酶（５－ｌｉｐｏｘｙｇｅｎａｓｅ
